Eledon Pharmaceuticals, Inc. (ELDN)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds | - | -10,060 | ||
| Other income, net | 1,224 | 1,409 | ||
| Research and development | 20,276 | 13,531 | ||
| General and administrative | 4,457 | 4,433 | ||
| Total operating expenses | 24,733 | 17,964 | ||
| Loss from operations | -24,733 | -17,964 | ||
| Change in fair value of warrant liabilities | -12,293 | - | ||
| Net loss | -11,216 | -6,495 | ||
| Earnings per share, basic, total | -0.13 | -0.08 | ||
| Net loss per share, diluted | -0.13 | -0.08 | ||
| Weighted average number of shares outstanding, basic, total | 77,156,068 | 77,126,763 | ||
| Weighted average number of shares outstanding, diluted, total | 77,156,068 | 77,126,763 | ||